- Takeda's total debt was $35,698.6 million, down 22.1% from the previous year.
- Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%.
- Gilead's key HIV drug is beginning to feel increased competition from ViiV Healthcare's drug.
- Takeda management expects ENTYVIO sales to reach 659 billion yen in 2022, up 26% from 2021.
- Sales of Trodelvy, which Gilead acquired for $21 billion in 2020, were $146 million in Q1 2022, up 23.7% from the previous quarter.
For further details see:
Takeda Pharmaceutical Vs. Gilead Sciences: Who Is The Dividend King?